Table 1 Baseline characteristics of study participants (n = 75)
From: Treatment adherence and health outcomes in patients with bronchiectasis
Characteristic | Result | |
|---|---|---|
Age, yr | 64 ± 8 | |
Gender, M/F | 24 (32)/51 (68) | |
Occupational status, n (%) | Employed/self-employed | 18 (24) |
Retired | 57 (76) | |
Level of education, n (%) | Less than high school | 14 (19) |
High school | 54 (72) | |
University | 7 (9) | |
Marital status, n (%) | Married or with a partner | 57 (76) |
Not married or not with a partner | 18 (24) | |
FEV1, L | 1.34 ± 0.6 | |
FEV1,% predicted | 61 ± 25 | |
Smoking status, n (%) | Never | 53 (71%) |
Current or ex | 22 (29%) | |
Aetiology, n (%) | Post-infection | 32 (43%) |
Idiopathic | 16 (21%) | |
Rheumatoid arthritis | 8 (11%) | |
COPD | 5 (7%) | |
Asthma | 3 (4%) | |
Other | 11 (15%) | |
Prescribed medicines | 12 ± 5 | |
Inhaled antibiotics, n (%) | Colistin | 64 (85%) |
Tobramycin | 11 (15%) | |
Other respiratory medicines, n (%) | ||
Oral medicines | Azithromycin | 38 (51%) |
Oral steroids | 19 (25%) | |
Mucolytics | 10 (13%) | |
Leukotriene receptor antagonists | 8 (11%) | |
Theophylline | 7 (9%) | |
Co-trimoxazole | 1 (1%) | |
Salbutamol | 1 (1%) | |
Inhaled medicines | Short-acting beta2 agonists | 67 (89%) |
Inhaled corticosteroids | 65 (87%) | |
Antimuscarinics | 31 (41%) | |
Long-acting beta2 agonists | 2 (3%) | |
Nebulised medicines | Short-acting beta2 agonists | 55 (73%) |
Isotonic saline | 25 (33%) | |
Ipratropium bromide with salbutamol | 3 (4%) | |
Hypertonic saline | 1 (1%) | |
Budesonide | 1 (1%) | |
Airway clearance | Active cycle of breathing technique | 39 (53%) |
Acapella® | 45 (61%) | |
QOL-B | Physical functioning | 31 ± 26 |
Role functioning | 45 ± 28 | |
Vitality functioning | 37 ± 20 | |
Social functioning | 42 ± 26 | |
Emotional functioning | 73 ± 21 | |
Treatment burden | 56 ± 20 | |
Health perceptions | 39 ± 19 | |
Respiratory symptoms | 53 ± 21 | |